United States Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2017

August 2017 | 107 pages | ID: U4777F65D9EEN
QYResearch

Abstracts

In this report, the United States Pulmonary Arterial Hypertension (PAH) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Pulmonary Arterial Hypertension (PAH) Drugs in these regions, from 2012 to 2022 (forecast).

United States Pulmonary Arterial Hypertension (PAH) Drugs market competition by top manufacturers/players, with Pulmonary Arterial Hypertension (PAH) Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Actelion Pharmaceuticals
• DAIICHI SANKYO
• GlaxoSmithKline
• Novartis
• United Therapeutics
• AADi
• Actelion Pharmaceuticals
• Aires Pharmaceuticals
• Arena Pharmaceuticals
• Asklepion Pharmaceuticals
• AstraZeneca
• Bayer Healthcare
• Berlin Cures
• BIAL
• Eiger BioPharmaceuticals

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• Inhalation
• Injectables
• Oral administration

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Pulmonary Arterial Hypertension (PAH) Drugs for each application, including

• ERAs
• Prostacyclin analogs
• PDE inhibitors
• sGC stimulators

Contents

United States Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2017

1 PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS OVERVIEW

1.1 Product Overview and Scope of Pulmonary Arterial Hypertension (PAH) Drugs
1.2 Classification of Pulmonary Arterial Hypertension (PAH) Drugs by Product Category
  1.2.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Inhalation
  1.2.4 Injectables
  1.2.5 Oral administration
1.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Market by Application/End Users
  1.3.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 ERAs
  1.3.3 Prostacyclin analogs
  1.3.4 PDE inhibitors
  1.3.5 sGC stimulators
1.4 United States Pulmonary Arterial Hypertension (PAH) Drugs Market by Region
  1.4.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Pulmonary Arterial Hypertension (PAH) Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Pulmonary Arterial Hypertension (PAH) Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Pulmonary Arterial Hypertension (PAH) Drugs Status and Prospect (2012-2022)
  1.4.5 New England Pulmonary Arterial Hypertension (PAH) Drugs Status and Prospect (2012-2022)
  1.4.6 The South Pulmonary Arterial Hypertension (PAH) Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Pulmonary Arterial Hypertension (PAH) Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Pulmonary Arterial Hypertension (PAH) Drugs (2012-2022)
  1.5.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Competitive Situation and Trends
  2.4.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Concentration Rate
  2.4.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Price by Region (2012-2017)

4 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2012-2017)
4.4 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Actelion Pharmaceuticals
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 DAIICHI SANKYO
  6.2.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 GlaxoSmithKline
  6.3.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Novartis
  6.4.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 United Therapeutics
  6.5.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 AADi
  6.6.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Actelion Pharmaceuticals
  6.7.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Aires Pharmaceuticals
  6.8.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Arena Pharmaceuticals
  6.9.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Asklepion Pharmaceuticals
  6.10.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Asklepion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 AstraZeneca
6.12 Bayer Healthcare
6.13 Berlin Cures
6.14 BIAL
6.15 Eiger BioPharmaceuticals

7 PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MANUFACTURING COST ANALYSIS

7.1 Pulmonary Arterial Hypertension (PAH) Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Pulmonary Arterial Hypertension (PAH) Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Pulmonary Arterial Hypertension (PAH) Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Pulmonary Arterial Hypertension (PAH) Drugs
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size (K Units) by Type (2012-2022)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Inhalation Product Picture
Figure Injectables Product Picture
Figure Oral administration Product Picture
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Application in 2016
Figure ERAs Examples
Figure Prostacyclin analogs Examples
Figure PDE inhibitors Examples
Figure sGC stimulators Examples
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2022)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Players/Suppliers
Figure 2017 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Players/Suppliers
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Players/Suppliers
Table United States Market Pulmonary Arterial Hypertension (PAH) Drugs Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Pulmonary Arterial Hypertension (PAH) Drugs Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Market Share of Top 3 Players/Suppliers
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Pulmonary Arterial Hypertension (PAH) Drugs Product Category
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Region (2012-2017)
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Region (2012-2017)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Region (2012-2017)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region in 2016
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Region (2012-2017)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2012-2017)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region in 2016
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Unit) by Region (2012-2017)
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Type (2012-2017)
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2012-2017)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2012-2017)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type in 2016
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Type (2012-2017)
Figure Revenue Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Type in 2016
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Unit) by Types (2012-2017)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate by Type (2012-2017)
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Application (2012-2017)
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2012-2017)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2012-2017)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application in 2016
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate by Application (2012-2017)
Table Actelion Pharmaceuticals Basic Information List
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)
Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)
Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)
Table DAIICHI SANKYO Basic Information List
Table DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)
Figure DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)
Figure DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)
Table GlaxoSmithKline Basic Information List
Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)
Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)
Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)
Table Novartis Basic Information List
Table Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)
Figure Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)
Figure Novartis Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)
Table United Therapeutics Basic Information List
Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)
Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)
Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)
Table AADi Basic Information List
Table AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)
Figure AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)
Figure AADi Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)
Table Actelion Pharmaceuticals Basic Information List
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)
Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)
Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)
Table Aires Pharmaceuticals Basic Information List
Table Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)
Figure Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)
Figure Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)
Table Arena Pharmaceuticals Basic Information List
Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)
Figure Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)
Figure Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)
Table Asklepion Pharmaceuticals Basic Information List
Table Asklepion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Asklepion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (2012-2017)
Figure Asklepion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in United States (2012-2017)
Figure Asklepion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in United States (2012-2017)
Table AstraZeneca Basic Information List
Table Bayer Healthcare Basic Information List
Table Berlin Cures Basic Information List
Table BIAL Basic Information List
Table Eiger BioPharmaceuticals Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Pulmonary Arterial Hypertension (PAH) Drugs
Figure Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Drugs
Figure Pulmonary Arterial Hypertension (PAH) Drugs Industrial Chain Analysis
Table Raw Materials Sources of Pulmonary Arterial Hypertension (PAH) Drugs Major Players/Suppliers in 2016
Table Major Buyers of Pulmonary Arterial Hypertension (PAH) Drugs
Table Distributors/Traders List
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Unit) Trend Forecast (2017-2022)
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) Forecast by Type in 2022
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) Forecast by Application in 2022
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources